The Oncology Institute, Inc. (NASDAQ:TOI) Director Buys $94,184.48 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala purchased 90,562 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the completion of the acquisition, the director now directly owns 224,971 shares in the company, valued at $233,969.84. The trade was a 67.38 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oncology Institute Trading Up 2.7 %

NASDAQ:TOI opened at $1.14 on Friday. The Oncology Institute, Inc. has a 1 year low of $0.13 and a 1 year high of $1.63. The stock’s fifty day moving average price is $0.86 and its two-hundred day moving average price is $0.48. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The company has a market cap of $86.14 million, a P/E ratio of -1.46 and a beta of 0.41.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). The firm had revenue of $100.27 million during the quarter, compared to analysts’ expectations of $109.15 million. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TOI. Jane Street Group LLC boosted its holdings in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after acquiring an additional 109,769 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Oncology Institute in the 4th quarter worth $41,000. FreeGulliver LLC grew its stake in shares of Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after purchasing an additional 412,578 shares during the period. Finally, Tiff Advisory Services LLC increased its holdings in Oncology Institute by 13.2% during the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock valued at $921,000 after buying an additional 346,256 shares during the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.